85
Participants
Start Date
May 23, 2013
Primary Completion Date
December 4, 2020
Study Completion Date
December 4, 2020
Dabrafenib
Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.
Novartis Investigative Site, Parkville
Novartis Investigative Site, New York
Novartis Investigative Site, Berlin
Novartis Investigative Site, Marseille
Novartis Investigative Site, Milan
Novartis Investigative Site, Baltimore
Novartis Investigative Site, Madrid
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Cincinnati
Novartis Investigative Site, Ramat Gan
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Paris
Novartis Investigative Site, Paris
Novartis Investigative Site, Jerusalem
Novartis Investigative Site, Orange
Novartis Investigative Site, Regensburg
Novartis Investigative Site, Villejuif
Novartis Investigative Site, Seattle
Novartis Investigative Site, Phoenix
Novartis Investigative Site, Boston
Novartis Investigative Site, Memphis
Novartis Investigative Site, Toronto
Novartis Investigative Site, Copenhagen
Novartis Investigative Site, Esplugues de Llobregat. Barcelona
Novartis Investigative Site, Sutton
Novartis Investigative Site, London
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY